These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

199 related articles for article (PubMed ID: 27804867)

  • 1. Medicinal Chemistry Insights into Novel HDAC Inhibitors: An Updated Patent Review (2012-2016).
    Zhan P; Wang X; Liu X; Suzuki T
    Recent Pat Anticancer Drug Discov; 2017; 12(1):16-34. PubMed ID: 27804867
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Selective and nonselective HDAC8 inhibitors: a therapeutic patent review.
    Adhikari N; Amin SA; Jha T
    Pharm Pat Anal; 2018 Nov; 7(6):259-276. PubMed ID: 30632447
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Recent progress in the development of histone deacetylase inhibitors as anti-cancer agents.
    Zhang L; Lei J; Shan Y; Yang H; Song M; Ma Y
    Mini Rev Med Chem; 2013 Dec; 13(14):1999-2013. PubMed ID: 24160707
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Profiling technologies for the identification and characterization of small-molecule histone deacetylase inhibitors.
    Liao D
    Drug Discov Today Technol; 2015 Nov; 18():24-8. PubMed ID: 26723889
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Inside HDAC with HDAC inhibitors.
    Bertrand P
    Eur J Med Chem; 2010 Jun; 45(6):2095-116. PubMed ID: 20223566
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Current trends in development of HDAC-based chemotherapeutics.
    Cheshmazar N; Hamzeh-Mivehroud M; Nozad Charoudeh H; Hemmati S; Melesina J; Dastmalchi S
    Life Sci; 2022 Nov; 308():120946. PubMed ID: 36096240
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Identification of type-specific anticancer histone deacetylase inhibitors: road to success.
    Noureen N; Rashid H; Kalsoom S
    Cancer Chemother Pharmacol; 2010 Sep; 66(4):625-33. PubMed ID: 20401613
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Inside HDACs with more selective HDAC inhibitors.
    Roche J; Bertrand P
    Eur J Med Chem; 2016 Oct; 121():451-483. PubMed ID: 27318122
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Histone deacetylase (HDAC) inhibitors in cancer: a patent review (2017-present).
    Zhao C; Dong H; Xu Q; Zhang Y
    Expert Opin Ther Pat; 2020 Apr; 30(4):263-274. PubMed ID: 32008402
    [No Abstract]   [Full Text] [Related]  

  • 10. Recent progress on HDAC inhibitors with dual targeting capabilities for cancer treatment.
    Peng X; Sun Z; Kuang P; Chen J
    Eur J Med Chem; 2020 Dec; 208():112831. PubMed ID: 32961382
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Novel histone deacetylase 6 (HDAC6) selective inhibitors: a patent evaluation (WO2014181137).
    Simões-Pires CA; Bertrand P; Cuendet M
    Expert Opin Ther Pat; 2017 Mar; 27(3):229-236. PubMed ID: 28092474
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Selective histone deacetylase small molecule inhibitors: recent progress and perspectives.
    Qin HT; Li HQ; Liu F
    Expert Opin Ther Pat; 2017 May; 27(5):621-636. PubMed ID: 28033734
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Development and therapeutic impact of HDAC6-selective inhibitors.
    Dallavalle S; Pisano C; Zunino F
    Biochem Pharmacol; 2012 Sep; 84(6):756-65. PubMed ID: 22728920
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Kinase and Histone Deacetylase Hybrid Inhibitors for Cancer Therapy.
    Luan Y; Li J; Bernatchez JA; Li R
    J Med Chem; 2019 Apr; 62(7):3171-3183. PubMed ID: 30418766
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Why Hydroxamates May Not Be the Best Histone Deacetylase Inhibitors--What Some May Have Forgotten or Would Rather Forget?
    Shen S; Kozikowski AP
    ChemMedChem; 2016 Jan; 11(1):15-21. PubMed ID: 26603496
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Small-molecule inhibitors of histone deacetylase for the treatment of cancer and non-cancer diseases: a patent review (2011 - 2013).
    Valente S; Mai A
    Expert Opin Ther Pat; 2014 Apr; 24(4):401-15. PubMed ID: 24397271
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Novel HDAC6 isoform selective chiral small molecule histone deacetylase inhibitors.
    Smil DV; Manku S; Chantigny YA; Leit S; Wahhab A; Yan TP; Fournel M; Maroun C; Li Z; Lemieux AM; Nicolescu A; Rahil J; Lefebvre S; Panetta A; Besterman JM; Déziel R
    Bioorg Med Chem Lett; 2009 Feb; 19(3):688-92. PubMed ID: 19111466
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Thirty Years of HDAC Inhibitors: 2020 Insight and Hindsight.
    Ho TCS; Chan AHY; Ganesan A
    J Med Chem; 2020 Nov; 63(21):12460-12484. PubMed ID: 32608981
    [TBL] [Abstract][Full Text] [Related]  

  • 19. An updated patent review of histone deacetylase (HDAC) inhibitors in cancer (2020 - present).
    Liu YM; Liou JP
    Expert Opin Ther Pat; 2023; 33(5):349-369. PubMed ID: 37249104
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Histone deacetylase inhibitors: a patent review (2009 - 2011).
    Carafa V; Miceli M; Altucci L; Nebbioso A
    Expert Opin Ther Pat; 2013 Jan; 23(1):1-17. PubMed ID: 23094822
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.